191 related articles for article (PubMed ID: 28399519)
1. Pharmacokinetic and Pharmacodynamic Modeling of MOD-4023, a Long-Acting Human Growth Hormone, in Growth Hormone Deficiency Children.
Fisher DM; Rosenfeld RG; Jaron-Mendelson M; Amitzi L; Koren R; Hart G
Horm Res Paediatr; 2017; 87(5):324-332. PubMed ID: 28399519
[TBL] [Abstract][Full Text] [Related]
2. Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children.
Zelinska N; Iotova V; Skorodok J; Malievsky O; Peterkova V; Samsonova L; Rosenfeld RG; Zadik Z; Jaron-Mendelson M; Koren R; Amitzi L; Raduk D; Hershkovitz O; Hart G
J Clin Endocrinol Metab; 2017 May; 102(5):1578-1587. PubMed ID: 28323965
[TBL] [Abstract][Full Text] [Related]
3. In Vitro and in Vivo Characterization of MOD-4023, a Long-Acting Carboxy-Terminal Peptide (CTP)-Modified Human Growth Hormone.
Hershkovitz O; Bar-Ilan A; Guy R; Felikman Y; Moschcovich L; Hwa V; Rosenfeld RG; Fima E; Hart G
Mol Pharm; 2016 Feb; 13(2):631-9. PubMed ID: 26713839
[TBL] [Abstract][Full Text] [Related]
4. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial.
Battelino T; Rasmussen MH; De Schepper J; Zuckerman-Levin N; Gucev Z; Sävendahl L;
Clin Endocrinol (Oxf); 2017 Oct; 87(4):350-358. PubMed ID: 28656605
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient children.
Kemp SF; Fielder PJ; Attie KM; Blethen SL; Reiter EO; Ford KM; Marian M; Dao LN; Lee HJ; Saenger P
J Clin Endocrinol Metab; 2004 Jul; 89(7):3234-40. PubMed ID: 15240597
[TBL] [Abstract][Full Text] [Related]
6. MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults.
Strasburger CJ; Vanuga P; Payer J; Pfeifer M; Popovic V; Bajnok L; Góth M; Olšovská V; Trejbalová L; Vadasz J; Fima E; Koren R; Amitzi L; Bidlingmaier M; Hershkovitz O; Hart G; Biller BMK
Eur J Endocrinol; 2017 Mar; 176(3):283-294. PubMed ID: 27932411
[TBL] [Abstract][Full Text] [Related]
7. IGF-I and IGF binding protein-3 levels during initial GH dosage step-up are indicators of GH sensitivity in GH-deficient children and short children born small for gestational age.
Ranke MB; Traunecker R; Martin DD; Schweizer R; Schwarze CP; Wollmann HA; Binder G
Horm Res; 2005; 64(2):68-76. PubMed ID: 16113581
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials.
Juul RV; Rasmussen MH; Agersø H; Overgaard RV
Clin Pharmacokinet; 2019 Jan; 58(1):63-75. PubMed ID: 29671202
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, Pharmacodynamics, and Safety of a Long-Acting Human Growth Hormone (MOD-4023) in Healthy Japanese and Caucasian Adults.
Kramer WG; Jaron-Mendelson M; Koren R; Hershkovitz O; Hart G
Clin Pharmacol Drug Dev; 2018 Jun; 7(5):554-563. PubMed ID: 29136343
[TBL] [Abstract][Full Text] [Related]
11. Three weekly injections (TWI) of low-dose growth hormone (GH) restore low normal circulating IGF-I concentrations and reverse cardiac abnormalities associated with adult onset GH deficiency (GHD).
Pincelli AI; Bragato R; Scacchi M; Branzi G; Osculati G; Viarengo R; Leonetti G; Cavagnini F
J Endocrinol Invest; 2003 May; 26(5):420-8. PubMed ID: 12906369
[TBL] [Abstract][Full Text] [Related]
12. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment.
Feigerlová E; Diene G; Oliver I; Gennero I; Salles JP; Arnaud C; Tauber M
J Clin Endocrinol Metab; 2010 Oct; 95(10):4600-8. PubMed ID: 20926543
[TBL] [Abstract][Full Text] [Related]
13. Optimal Monitoring of Weekly IGF-I Levels During Growth Hormone Therapy With Once-Weekly Somapacitan.
Juul Kildemoes R; Højby Rasmussen M; Agersø H; Overgaard RV
J Clin Endocrinol Metab; 2021 Jan; 106(2):567-576. PubMed ID: 33313798
[TBL] [Abstract][Full Text] [Related]
14. Serum leptin and IGF-I during growth hormone treatment in chronic renal failure.
Patel L; Webb NJ; Bradbury MG; Zaman N; Smith P; Lewis MA; Postlethwaite RJ; Price DA; Clayton PE
Pediatr Nephrol; 2002 Aug; 17(8):643-7. PubMed ID: 12185474
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic/pharmacodynamic analysis of PEG-rhGH enhances confidence in exploring dosing schemes with longer intervals.
Cheng R; Zhao Q; Zhong G; Xu J; Zheng Z; Xi L; Zhang M; Ni J; Hu P; Luo F; Lu W
Eur J Pharm Sci; 2022 Dec; 179():106304. PubMed ID: 36209987
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic profile of a new sustained-release GH formulation, LB03002, in children with GH deficiency.
Peter F; Savoy C; Ji HJ; Juhasz M; Bidlingmaier M; Saenger P
Eur J Endocrinol; 2009 Mar; 160(3):349-55. PubMed ID: 19074465
[TBL] [Abstract][Full Text] [Related]
17. Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children.
Cohen P; Germak J; Rogol AD; Weng W; Kappelgaard AM; Rosenfeld RG;
J Clin Endocrinol Metab; 2010 May; 95(5):2089-98. PubMed ID: 20207829
[TBL] [Abstract][Full Text] [Related]
18. Age related IGF-I changes and IGF-I generation in thalassemia major.
Soliman AT; Abushahin A; Abohezeima K; Khalafallah H; Adel A; Elawwa A; Elmulla N
Pediatr Endocrinol Rev; 2011 Mar; 8 Suppl 2():278-83. PubMed ID: 21705978
[TBL] [Abstract][Full Text] [Related]
19. A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency.
Moore WV; Nguyen HJ; Kletter GB; Miller BS; Rogers D; Ng D; Moore JA; Humphriss E; Cleland JL; Bright GM
J Clin Endocrinol Metab; 2016 Mar; 101(3):1091-7. PubMed ID: 26672637
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and growth hormone (GH) therapy in children with GH deficiency: experience in King Chulalongkorn Memorial Hospital, Thailand.
Wacharasindhu S; Supornsilchai V; Aroonparkmongkol S; Srivuthana S
J Med Assoc Thai; 2007 Oct; 90(10):2047-52. PubMed ID: 18041422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
